BIOMAT Database Logo BIOMAT Database Logo

Antibacterial activity of liposomal amikacin against Pseudomonas aeruginosa in vitro. 1995

M Antos, and E A Trafny, and J Grzybowski
Department of Microbiology, Military Institute of Hygiene and Epidemiology, Warszawa, Poland.

The influence of liposomal amikacin on Pseudomonas aeruginosa was studied. P. aeruginosa clinical isolates caused release of encapsulated amikacin from liposomes. The liposomal amikacin proved to be active as bactericidal agent after 3 h of incubation with P. aeruginosa. Incubation of P. aeruginosa with liposomal amikacin resulted in inhibition of the growth when equivalent of 2 MIC was added but not when equivalent of 1 MIC was added. Susceptibility of bacterial isolates to the liposomal amikacin varied with bacterial strain used, but generally encapsulation of amikacin did not enhance their antibacterial activity.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D000583 Amikacin A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics. A.M.K,Amikacin Sulfate,Amikacina Medical,Amikacina Normon,Amikafur,Amikalem,Amikason's,Amikayect,Amikin,Amiklin,Amukin,BB-K 8,BB-K8,Biclin,Biklin,Gamikal,Kanbine,Oprad,Yectamid,BB K 8,BB K8,BBK 8,BBK8,Medical, Amikacina,Normon, Amikacina,Sulfate, Amikacin
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

M Antos, and E A Trafny, and J Grzybowski
Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa.
October 1995, The Journal of antimicrobial chemotherapy,
M Antos, and E A Trafny, and J Grzybowski
In vitro activity of ceftriaxone and amikacin against Pseudomonas aeruginosa.
January 1991, Chemotherapy,
M Antos, and E A Trafny, and J Grzybowski
Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study.
March 2006, International journal of antimicrobial agents,
M Antos, and E A Trafny, and J Grzybowski
In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains.
June 2006, International journal of pharmaceutics,
M Antos, and E A Trafny, and J Grzybowski
In-vitro activity of imipenem and amikacin combinations against resistant Pseudomonas aeruginosa.
June 1993, The Journal of antimicrobial chemotherapy,
M Antos, and E A Trafny, and J Grzybowski
Activity of amikacin, gentamicin and kanamycin against Pseudomonas aeruginosa.
January 1976, The Journal of international medical research,
M Antos, and E A Trafny, and J Grzybowski
In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa.
June 1978, Antimicrobial agents and chemotherapy,
M Antos, and E A Trafny, and J Grzybowski
In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
February 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
M Antos, and E A Trafny, and J Grzybowski
Study of in vitro antibacterial activity of 19 antimicrobial agents against Pseudomonas aeruginosa.
April 1989, Chinese medical journal,
M Antos, and E A Trafny, and J Grzybowski
In Vitro Antibacterial Activity of Ethanol Extracts of Cinnamomum zeylanicum against Pseudomonas aeruginosa.
April 2020, Mymensingh medical journal : MMJ,
Copied contents to your clipboard!